Francesco Draetta is a Principal at Omega. He currently serves on the board of directors of Chord Therapeutics, and as a board observer for Amunix Pharmaceuticals and Lexeo Therapeutics. Prior to joining Omega, Francesco was an Analyst at Brookside Mezzanine Partners, a mezzanine fund investing in subordinated debt and minority equity in small- to mid-size companies throughout the U.S., where he focused on due diligence, deal management, and investor relations. Prior to Brookside Mezzanine Partners, he was an Associate at Commonfund Capital, the private capital arm of Commonfund, where he focused on due diligence, manager selection, investment management, and investor relations. Francesco began his career at Omega as an Analyst.
Francesco graduated cum laude from the Isenberg School of Management at the University of Massachusetts Amherst with a BBA in Finance and Operations Management. He is also a CFA charterholder, a CAIA charterholder, and a Certified FRM.
Francesco is attending / has attended:
VSVC West 2021